UCP2 and Alzheimer disease: OA (10 mg/kg) has been shown to inhibit Aβ25-35-induced cellular and synaptic toxicity (Wang et al., 2018), Aβ levels, and neuronal apoptosis, and reduce ROS levels by regulating uncoupling protein-2 (UCP2) expression through stanniocalcin-1 (STC-1), which can alleviate oxidative stress damage and play a role in the treatment of AD (Guo et al., 2020).